- Home
- YALA vs AVXL Comparison
YALA vs AVXL Comparison
Compare YALA & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YALA
- AVXL
- Stock Information
- Founded
- YALA 2016
- AVXL 2004
- Country
- YALA United Arab Emirates
- AVXL United States
- Employees
- YALA N/A
- AVXL N/A
- Industry
- YALA Computer Software: Programming Data Processing
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YALA Technology
- AVXL Health Care
- Exchange
- YALA Nasdaq
- AVXL Nasdaq
- Market Cap
- YALA N/A
- AVXL 779.5M
- IPO Year
- YALA 2020
- AVXL N/A
- Fundamental
- Price
- YALA $5.22
- AVXL $8.58
- Analyst Decision
- YALA
- AVXL Strong Buy
- Analyst Count
- YALA 0
- AVXL 2
- Target Price
- YALA N/A
- AVXL $44.00
- AVG Volume (30 Days)
- YALA 612.4K
- AVXL 1.0M
- Earning Date
- YALA 03-10-2025
- AVXL 05-08-2025
- Dividend Yield
- YALA N/A
- AVXL N/A
- EPS Growth
- YALA 13.85
- AVXL N/A
- EPS
- YALA 0.74
- AVXL N/A
- Revenue
- YALA $339,675,845.00
- AVXL N/A
- Revenue This Year
- YALA $10.73
- AVXL N/A
- Revenue Next Year
- YALA $1.28
- AVXL N/A
- P/E Ratio
- YALA $7.31
- AVXL N/A
- Revenue Growth
- YALA 6.52
- AVXL N/A
- 52 Week Low
- YALA $3.71
- AVXL $3.25
- 52 Week High
- YALA $5.82
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- YALA 62.32
- AVXL 41.53
- Support Level
- YALA $5.25
- AVXL $9.21
- Resistance Level
- YALA $5.82
- AVXL $9.87
- Average True Range (ATR)
- YALA 0.28
- AVXL 0.54
- MACD
- YALA 0.04
- AVXL -0.06
- Stochastic Oscillator
- YALA 62.73
- AVXL 10.50
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.